Group One Trading’s Co-Diagnostics CODX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-1,810
Closed -$19.7K 8252
2025
Q3
$18.7K Buy
1,810
+1,775
+5,071% +$16.5K ﹤0.01% 6744
2025
Q2
$291 Buy
+35
New +$327 ﹤0.01% 7707
2025
Q1
Sell
-1,345
Closed -$30.3K 7690
2024
Q4
$30.3K Buy
1,345
+9
+0.7% +$284 ﹤0.01% 5430
2024
Q3
$50.1K Buy
1,336
+455
+52% +$17.5K ﹤0.01% 4651
2024
Q2
$33.1K Buy
881
+320
+57% +$11.6K ﹤0.01% 4838
2024
Q1
$18.9K Buy
561
+183
+48% +$6.63K ﹤0.01% 5462
2023
Q4
$15.1K Buy
378
+373
+7,460% +$13.1K ﹤0.01% 5945
2023
Q3
$153 Buy
+5
New +$189 ﹤0.01% 7446
2023
Q1
Sell
-298
Closed -$23.9K 7302
2022
Q4
$22.5K Sell
298
-2,376
-89% -$222K ﹤0.01% 5526
2022
Q3
$258K Sell
2,674
-600
-18% -$83.9K ﹤0.01% 3903
2022
Q2
$551K Buy
3,274
+1,387
+74% +$211K ﹤0.01% 3325
2022
Q1
$350K Buy
1,887
+83
+5% +$17.2K ﹤0.01% 4219
2021
Q4
$483K Sell
1,804
-338
-16% -$88.7K ﹤0.01% 4172
2021
Q3
$625K Buy
2,142
+661
+45% +$193K ﹤0.01% 3948
2021
Q2
$367K Sell
1,481
-816
-36% -$210K ﹤0.01% 4565
2021
Q1
$657K Buy
+2,297
New +$917K ﹤0.01% 3720

Other funds holding CODX

Group One Trading's CODX Position: Q4 2025 in Review

Group One Trading sold out of Co-Diagnostics (CODX) in Q4 2025, closing a stake of 1,810 shares — an estimated $19.7K sold.

Group One Trading first reported a position in CODX in Q1 2021 and held it in 16 quarters. The position peaked at $657K in Q1 2021. 30 funds tracked by Wall St. Rank hold CODX as of Q4 2025.

  • Group One Trading reported no remaining Co-Diagnostics position as of Q4 2025 after selling out during the quarter.
  • Group One Trading sold 1,810 Co-Diagnostics shares in Q4 2025, an estimated $19.7K.
  • Group One Trading first reported a position in Co-Diagnostics in Q1 2021 and held it in 16 quarters.
  • Group One Trading's Co-Diagnostics position peaked at $657K in Q1 2021.
  • 30 funds tracked by Wall St. Rank held Co-Diagnostics as of Q4 2025.

Based on Group One Trading's 13F filing for Q4 2025, filed 12 Feb 2026.